Mr. Musk’s supporters say he may quit if shareholders don’t approve a trillion-dollar package. Some investors say it’s excessive and would give him too much sway.
Category: Corporations
-
Delaware’s Highest Court Considers Elon Musk’s Tesla Pay Plan
The justices on the state Supreme Court heard arguments in a long dispute about whether the Tesla chief executive’s compensation was fair to shareholders.
-
Trump to Announce a Drug Pricing Deal With AstraZeneca
The move would follow a similar agreement with Pfizer. Other companies are engaged in talks with the White House that would help them avoid tariffs on their products overseas.
-
Boeing Will Regain Ability to Certify Some Planes From F.A.A.
The Federal Aviation Administration said the aerospace company will be allowed to approve some new 737 Max and 787 Dreamliner jets.
-
Why Companies Like Disney and Paramount Are Caving to Trump
When broadcasters like CBS and ABC surrendered to the president, it looked as if they lacked backbone. The explanation runs much deeper.
-
Chevron’s Boss Says the World Will Need Oil for a ‘Long, Long Time’
Mike Wirth, who has seen many booms and busts over the more than 40 years he has been with the energy giant, said that “when the world stops using oil and gas, we’ll stop looking for it.”
-
Spirit Airlines Files for Bankruptcy for 2nd Time in a Year
The troubled carrier last exited Chapter 11 in March. It said more could be done to stabilize the company with a second filing.
-
Larry Ellison Wants to Do Good, Do Research and Make a Profit
Oracle’s co-founder and the world’s second-richest person pledges to concentrate his vast resources on his own research institute and for-profit ventures to address health, hunger and climate change.
-
UnitedHealth Grew to Be a Leviathan. Then Came the Backlash.
The conglomerate was viewed as one of the most successful companies in America, but patients are enraged and investors have lost faith in its business model.
-
UnitedHealth Grew to Be a Leviathan. Then Came the Backlash.
The conglomerate was viewed as one of the most successful companies in America, but patients are enraged and investors have lost faith in its business model.